©The Author(s) 2025.
World J Hepatol. Dec 27, 2025; 17(12): 110966
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.110966
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.110966
Table 6 Examples of ongoing trials in autoimmune hepatitis
| Ref. | Treatment | Mechanism of action | Stage of development | |
| Mack et al[2], 2020; Whitehead and Kriegermeier[42], 2020; Reau et al[48], 2024 | 1 | Zetomipzomib | Immunoproteasome inhibitor | Phase 2 |
| 2 | Ianalumab, Belimumab | Antibody-dependent cellular cytotoxicity mediated B-cell depletion through B-cell activating factor inhibition | Phase 2/3 | |
| 3 | JKB-122 | Toll-like receptor-4 inhibition | Phase 2 | |
| 4 | Mesenchymal stromal cells | Induction of regulatory T-cell differentiation and suppression of lymphocyte activation | Phase 1/2 | |
| 5 | Synthetic preimplantation factor (s-PIF) | Creation of immunosuppressive and immunomodulatory environment of pregnancy | Phase 1 |
- Citation: Valamparampil J, Brown RM, McKiernan P. Refractory autoimmune hepatitis in children: Considerations for assessment and management. World J Hepatol 2025; 17(12): 110966
- URL: https://www.wjgnet.com/1948-5182/full/v17/i12/110966.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i12.110966